EGFR and non-small cell lung carcinoma: These findings suggest a role for ZEB1 in the persistence of the mesenchymal and CSC genotypes that are resistant to gefitinib in EGFR mutation‐positive NSCLC via the ZEB1‐miR200c‐BMI1 axis.